Fasting plus immunotherapy and chemotherapy before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether a 16-hour fast combined with the immunotherapy drug serplulimab and the chemotherapy regimen CAPEOX can shrink rectal tumors before surgery. It is for people with a specific type of rectal cancer (pMMR/MSS) that has not spread far and can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adenocarcinoma of the rectum, and the tumor's lower edge is less than 10 cm from the anal verge.
- Your cancer is at a stage where surgery is expected to completely remove it (R0 resection), as confirmed by a team of specialists.
- Your tumor is classified as MSS (microsatellite stable) or pMMR (mismatch repair proficient), and you have not had any prior systemic treatment for this cancer.
- You are in good general health (able to carry out daily activities) and do not have certain heart, liver, or infectious conditions.
- You have not had prior pelvic radiation or treatment with immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
This trial tests a shorter course of radiation given with chemotherapy and immunotherapy before surgery for rectal cancer that has high-risk features. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial compares two chemotherapy combinations given before surgery for low rectal cancer. One group gets a standard chemo pill (CAPOX), while the other gets a more intense combination of three chemo drugs plus an immunotherapy drug (PD-1 inhibitor) to see which approach works better at shrinking tumors.
Hear when a new pMMR/MSS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.